Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clofazimine - Novartis

Drug Profile

Clofazimine - Novartis

Alternative Names: B-663; LAM-320; Lamprene

Latest Information Update: 12 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College Dublin
  • Developer Alliance Pharma plc; Novartis; University College Dublin; University of Pretoria
  • Class Antibacterials; Antileprotics; Phenazines
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leprosy
  • Discontinued Crohn's disease; Liver cancer

Most Recent Events

  • 15 Apr 2019 Novartis Pharma terminates a phase IIb/III trial in Tuberculosis (Treatment-resistant) in Lithuania and Latvia prior to enrolment (PO) (EudraCT2015-004440-19)
  • 31 Dec 2018 Novartis announces intention to submit regulatory applications for Tuberculosis in 2021 (Novartis pipeline, March 2019)
  • 01 Mar 2016 Novartis Pharma plans a phase IIb/III trial in Tuberculosis (Treatment-resistant) in Lithuania, Kenya, Latvia, Peru, Philippines, Russia, South Africa and Thailand (PO) (EudraCT2015-004440-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top